Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Olivier Bylicki"'
Autor:
Elodie Valero-Biance, Frédéric Janvier, Audrey Ferrier, Antoine Bronstein, Olivier Ferraris, Carine Malle, Olivier Bylicki, Jean-Nicolas Tournier, A. Mayet, Anne Perisse, David Delarbre, Jacques Cobola, Nastasia Menoud
Publikováno v:
International Journal of Infectious Diseases
International Journal of Infectious Diseases, Elsevier, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International Journal of Infectious Diseases, Vol 112, Iss, Pp 8-12 (2021)
International Journal of Infectious Diseases, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International Journal of Infectious Diseases, Elsevier, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International Journal of Infectious Diseases, Vol 112, Iss, Pp 8-12 (2021)
International Journal of Infectious Diseases, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International audience; Objective: A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on the va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78568a3c3a8419a664f17add08bd4944
https://www.hal.inserm.fr/inserm-03651036/document
https://www.hal.inserm.fr/inserm-03651036/document
Autor:
Gilles Robinet, Christos Chouaid, Radj Gervais, Roland Schott, Florian Guisier, Chantal Decroisette, Jean-Bernard Auliac, Olivier Bylicki, Charles Ricordel, Laurent Greillier, Maurice Pérol, Benjamin Besse, Renaud Descourt
Publikováno v:
Future Oncology
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer withoutLay abstract Non-small-cell lung cancer (NSCLC) is the most frequent type of lung cancer. Most NSCLC patients are diagnosed wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d4948a536b358f6ce91b90b9bc53c5
https://inria.hal.science/hal-03526346
https://inria.hal.science/hal-03526346
Autor:
R. Lamy, Christos Chouaid, Hélène Doubre, Pierre Fournel, Olivier Bylicki, Isabelle Monnet, Radj Gervais, H. Janicot, Jean-Bernard Auliac, Florian Guisier, Maurice Pérol
Publikováno v:
Medicine
Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against epidermal growth-factor receptor (EG